Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

What Was Tested

This randomized controlled trial paper looks at Tirzepatide.

Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes.

Who Took Part

The abstract describes 731 patients taking part.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Tirzepatide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Tirzepatide could be set against what happens without it.

What Was Measured

Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes.

Topics PubMed links to this paper include Body Mass Index, Cardiovascular Diseases, Glucagon-Like Peptide 1, Heart Failure, Kaplan-Meier Estimate, Obesity and Quality of Life.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide in 731 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (The New England journal of medicine), a journal based in United States.

More context: the Tirzepatide compound page, all human trials.